Crystagen

Name: Crystagen
Brand: LyoPep

EDP tripeptide research reference · trade-name linkage and market sequences require verification

Lot-specific · Batch COACAS Confirm per batch COARUO

Batch COA

MOQ1 kit (10 vials) per SKU

Supplied formLinear tripeptide; H-Glu-Asp-Pro-OH (EDP)

Lead time14–21 days

Crystagen — Lot-specific lyophilized research peptide; confirm colour and cake condition on the released-lot COA

Crystagen — Lot-specific lyophilized research peptide; confirm colour and cake condition on the released-lot COA · Representative packaging image · verify the ordered lot

Representative packaging image · verify the ordered lot

Decision summary

Key benefits

Research applications include EDP identity qualification, controlled lymphocyte or immune-cell models, senescence-related marker assays, replication of patent experiments and analytical comparison with heterogeneous Thymalin or other short peptides
Patent claims and observational extract programmes are hypotheses or context, not approved efficacy claims for isolated EDP.

Published research context is presented for literature orientation only. It is not a dosing, treatment or human-use instruction.

Qualification data

Specifications to confirm against the released lot

CAS: Confirm per batch COA
Formula: C₁₄H₂₁N₃O₈
Molecular weight: 359.33 g/mol
Appearance: Lot-specific lyophilized research peptide; confirm colour and cake condition on the released-lot COA
Purity: Lot-specific chromatographic purity and quantitative peptide content; confirm both on the released-lot COA · target, verify batch COA
Storage: Follow the released-lot COA, SDS and formulation-specific stability statement. Temperature, light protection, container, shipping range and any prepared-solution hold time require evidence for the exact EDP form, counterion, matrix and concentration; capsule or sublingual product labels do not apply.
MOQ: 1 kit (10 vials) per SKU
Lead time: 14–21 days

PubChem CID 23624313

Qualification matrix

Identity, purity and content are separate release questions.

Identity

Confirm the stated molecule and supplied form. Start with the matching batch COA; request sequence-level evidence only when the buyer's written procedure requires it and availability or a separate scope has been agreed.

Purity

Review RP-HPLC method conditions, wavelength, integration and related-peak handling. A percentage without the method is not enough.

Content

Net peptide content is not the same as gross lyophilized powder weight. Ask which assay supports the stated amount and whether water/counter-ion is addressed.

Stability

Follow the storage condition stated on the batch COA or label from receipt onward.

Research context

What researchers study about Crystagen

Crystagen is a trade name generally associated with synthetic H-Glu-Asp-Pro-OH, EDP. PubChem CID 145455337 and US Patent 8,057,810 B2 support the EDP tripeptide, formula C₁₄H₂₁N₃O₈ and molecular weight 359.33 Da, but the patent does not use the names Crystagen or AC-6. The trade-name linkage is indirect through a Khavinson patent-family listing. Later literature places EDP in the lineage of thymic-extract research, but does not prove it was naturally isolated as the active ingredient of Thymalin. Conflicting commercial sequences make exact sequence, termini, counterion and supplied form order-critical.

EDP identity and method development; controlled lymphocyte, immune-cell, senescence and gene-expression models; replication of patent experiments; and analytical comparison with Thymalin or related short peptides
These are laboratory applications, not clinical indications.

Mechanism context

The question the literature is testing

The patent reports lymphocyte proliferation/differentiation observations and proposes restoration of tissue-specific protein synthesis. Broader Khavinson literature proposes chromatin, DNA/histone and gene-expression effects for short peptides. No specific receptor or complete causal pathway has been independently validated for isolated EDP, and results from Thymalin cannot be transferred automatically.

Evidence map

Research routes and exposure context

Evidence tierMixed evidence context

Research areaKhavinson bioregulators

Routes reported in sources

OralSublingual

Dose / exposure contextProtocol-specific; verify the cited primary source

Routes and exposure contexts summarize cited studies or approved finished-product labels. They are not instructions for administering this RUO material; no customer dose is provided.

Evidence boundaries

Compatibility, limitations and decision context

Not for human or veterinary use and not a food or dietary supplement
Historical supplement labels and reports of tolerability do not establish safety, pregnancy guidance, interaction safety or administration suitability for this RUO lot
Follow the SDS, institutional controls and appropriate PPE.

Interactions reported in the literature

No controlled combination or drug-interaction evidence was identified
Pairings with Thymogen, Vilon, Thymosin Alpha-1, TB-500 or other bioregulators are commercial or research hypotheses, not validated synergy, compatibility or safety guidance.

Literature context is not a supplier release result or human-use instruction. Follow your institution's approved laboratory risk assessment.

Batch documentation

Crystagen batch COAs

Laboratory: Manufacturer's QC laboratoryTests: HPLC purity · MS identity · endotoxin · fill amount

20 mg

Previews are blurred on purpose so the documents cannot be reused; third-party reports show their first page only. Sales sends the clear full version for the product and strength you ask about.

Independent test fails? Full refund.

Representative records, refreshed periodically

Published COAs show recent representative batches and may not be the newest. For a quote or shipment, sales confirms the lot and sends its COA.

Third-party reports, added progressively

Previews of the first page of third-party reports are on our Quality page and on the matching product pages; sales sends the full report on request. You can also send any vial from your order to an independent laboratory of your choice. Unless agreed otherwise in writing, the buyer pays for optional testing.

Help reviewing your COA

Need help reading a batch COA or third-party report? Sales can explain the test items, specifications and how the results relate to the lot under discussion.

On every batch COA: HPLC purity · MS identity · endotoxin · fill amount · Verify LyoPep

Ask for the current packet, not a generic certificate

Require exact EDP sequence and termini, supplied form/counterion, theoretical and observed high-resolution intact mass, orthogonal sequence evidence, stability-indicating HPLC purity and impurity profile, quantitative peptide content, water/counterion/residuals and lot-specific stability
Sterility, bacterial endotoxin and bioburden are separate tests
EDP/TKD/KED/Pro-Gln-Asn or ingredient-list inconsistencies are identity failures; price, packaging or an uncited efficacy percentage is not quality evidence.

Batch COA for the released lotHPLC purity with method contextMS identity resultEndotoxin resultFill amount (measured content per vial)SDS and handling statement

Available fills

Quote the fill and pack configuration you need

Reference SKUFillBase pack

CRY2020 mg10 vials

Handling

Plan storage before the parcel arrives

Follow the released-lot COA, SDS and formulation-specific stability statement. Temperature, light protection, container, shipping range and any prepared-solution hold time require evidence for the exact EDP form, counterion, matrix and concentration; capsule or sublingual product labels do not apply.

State the destination and timing so receipt can be planned, then move the material into its stated storage condition on arrival.

Buyer FAQ

Terms to settle before the purchase order

Can a buyer arrange third-party testing?+

Yes. You can send any vial from your order to an independent laboratory of your choice. If you want the laboratory, specification, sampling, method and acceptance rule agreed with us before testing, sales confirms them in writing. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

What if my own lab test shows the product is out of specification?+

Send any vial from your order to an independent laboratory of your choice. If the report shows the product does not meet the specification on its COA — purity below the stated minimum, or an identity that does not match — share the report with our sales team and we refund that product in full.

Does HPLC purity prove peptide content?+

No. Chromatographic purity describes the relative peak profile under a stated method. Identity, water, counter-ion, residual solvents and assay/content may require separate methods.

How should material be stored after delivery?+

Move it into the storage condition stated on the batch COA or label as soon as it arrives, and record the package condition on receipt.

How are payment terms handled?+

Available methods and milestones depend on order value, destination and project type. The pro forma invoice should state currency, bank details, fees, payment milestones and the release condition.

Why must the testing laboratory understand peptide chemistry?+

Free-base and salt forms, hydrophilic and hydrophobic sequences, aggregation and adsorption can change sample preparation and method suitability. Use a laboratory experienced with the molecule class.

External qualification references

WHO good storage and distribution practices ISO/IEC 17025 laboratory competence 21 CFR 211.84 component testing and supplier COA controls

These are buyer-qualification references, not claims that this RUO material is regulated, certified or released under those frameworks. Applicability depends on the buyer's workflow and jurisdiction.

Selected sources

Literature behind the research context

Identity: PubChem CID 145455337 and US Patent 8,057,810 B2; patent experimental context: US Patent 8,057,810 B2; indirect trade-name linkage: Khavinson patent-family listing and IL 194499. Related but non-equivalent contexts: PMID 14523363 for Thymalin plus Epithalamin and PMC8654498 for Thymalin extract. These sources do not establish purified EDP clinical efficacy, human dose or pharmacokinetics.

01
Peptide substance revealing an immunogeroprotective effect, pharmaceutical composition on its base and the method of its application
United States Patent and Trademark Office (assignee: Peptidpro LLC) · 2011 · regulatory/IP document (issued US patent, not peer-reviewed journal article)
Open source
02
Кристаген (Kristagen) — БАД product monograph
RLSNET.ru commercial professional pharmaceutical reference directory · 2022 · commercial professional pharmaceutical reference-directory entry
Open source
03
Кристаген — пептиды тимуса, 20 капсул (product page)
peptid.ru (official Khavinson Peptides brand site) · 2024 · company/manufacturer product page
Open source

Product FAQ

Questions buyers ask about Crystagen

What identity is best supported for Crystagen?+

PubChem CID 145455337 and US Patent 8,057,810 B2 support synthetic H-Glu-Asp-Pro-OH, EDP, formula C₁₄H₂₁N₃O₈ and molecular weight 359.33 Da. The patent does not use the names Crystagen or AC-6; that linkage comes indirectly from a Khavinson patent-family listing. Market pages also publish conflicting sequences. The order and COA must therefore state exact N-to-C sequence, termini, form/counterion and orthogonal identity results.

Can evidence for Thymalin be assigned to purified EDP?+

No. Thymalin is a heterogeneous thymic extract, while EDP is one defined synthetic tripeptide. Observations for an extract, or for a Thymalin-plus-Epithalamin programme, cannot establish efficacy, safety or mechanism of isolated EDP. Such records provide lineage context only and must retain the exact tested material.

Which quality controls address market mislabelling?+

Require the full EDP sequence and termini, theoretical and observed high-resolution intact mass, orthogonal sequence evidence, chromatographic purity and impurity profile, quantitative peptide content, counterion, water and residual solvents, and lot-specific stability. Compare every label and COA field for internal consistency; an EDP, TKD, KED, Pro-Gln-Asn or ingredient-list mismatch is a critical identity failure.

Evidence before order

Crystagen

Key benefits

Specifications to confirm against the released lot

Identity, purity and content are separate release questions.

What researchers study about Crystagen

The question the literature is testing

Research routes and exposure context

Compatibility, limitations and decision context

Interactions reported in the literature

Crystagen batch COAs

Ask for the current packet, not a generic certificate

Quote the fill and pack configuration you need

Plan storage before the parcel arrives

Terms to settle before the purchase order

Literature behind the research context

Peptide substance revealing an immunogeroprotective effect, pharmaceutical composition on its base and the method of its application

Кристаген (Kristagen) — БАД product monograph

Кристаген — пептиды тимуса, 20 капсул (product page)

Questions buyers ask about Crystagen

Buyer intelligence

Compare adjacent molecules and documentation needs.

Thymalin/Thymulin

Cortagen

Vesugen

Cardiogen